Neurobiological and Clinical Effects of Vitamin D in Psychiatric Symptoms: A Meta-Analysis and Systematic Review
Trends in Sciences · 20.03.2026 · 23 (8) · 13036
DOI: 10.48048/tis.2026.13036 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Trends in Sciences, online erschienen am 20.03.2026. Verfasst von Rina Hastuti Lubis und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Beyond its traditional function in maintaining calcium and phosphate homeostasis, vitamin D is now widely understood as a neuroactive steroid with regulatory effects on neural transmission, inflammatory modulation, and synaptic adaptability commonly referred to as neuroplasticity. Insufficient vitamin D status has been linked to disturbances in neuroimmune regulation as well as dysregulation of key neurotransmitter systems including dopaminergic, serotonergic, and glutamatergic pathways. This meta-analysis integrates findings from neurobiological research and clinical trials to examine the impact of vitamin D supplementation on a range of psychiatric manifestations, encompassing depressive symptoms, anxiety, psychotic features, and substance-related psychiatric disturbances. A total of 16 randomized controlled trials published between 2016 and 2025 were included, with data synthesized using a random-effects model and standardized assessment instruments such as the BDI, HAM-D, PHQ-9, BAI, STAI-S, and PANSS. The aggregated results indicate that vitamin D supplementation is associated with a small to moderate reduction in overall psychiatric symptom severity, as reflected by a standardized mean difference of −0.33 with a 95% confidence interval ranging from −0.54 to −0.12 and a statistically significant p value of 0.002. More consistent improvements were observed in mild-to-moderate depressive symptoms (SMD = −0.40; 95% CI −0.68 to −0.13; p = 0.004). Among individuals with substance use disorders, vitamin D significantly lowered depressive symptom scores (MD = −3.60; 95% CI −5.19 to −2.00; p < 0.0001), whereas its effects on anxiety symptoms were not significant (SMD = −0.74; 95% CI −1.71 to 0.23; p = 0.14). In psychotic disorders, vitamin D produced no significant improvements across PANSS domains (p > 0.05). vitamin D appears to modulate excitatory-inhibitory neurotransmission, oxidative stress regulation, inflammatory signaling, and monoaminergic pathways, supporting its role as an adjuvant rather than a primary therapeutic agent. Although beneficial in specific clinical contexts, vitamin D shows limited efficacy in severe psychiatric conditions characterized by longstanding neurocircuit abnormalities. Future large-scale RCTs are needed to determine optimal dosing strategies and clinical subgroups most likely to benefit. HIGHLIGHTS This study highlights that vitamin D supplementation is associated with reductions in psychiatric symptoms, especially depressive symptoms. Evidence supports its role as an adjunctive intervention rather than a primary treatment in psychiatric care. GRAPHICAL ABSTRACT
Zitieren
APA
Lubis, R. H., Yusuf, H., Khairan, K., & Sary, N. L. (2026). Neurobiological and Clinical Effects of Vitamin D in Psychiatric Symptoms: A Meta-Analysis and Systematic Review. Trends in Sciences, 23(8), 13036. https://doi.org/10.48048/tis.2026.13036
Vancouver
Lubis RH, Yusuf H, Khairan K, Sary NL. Neurobiological and Clinical Effects of Vitamin D in Psychiatric Symptoms: A Meta-Analysis and Systematic Review. Trends in Sciences. 2026;23(8):13036. doi:10.48048/tis.2026.13036
BibTeX
@article{Lubis2026,
author = {Lubis, Rina Hastuti and Yusuf, Hanifah and Khairan, Khairan and Sary, Nirwana Lazuardi},
title = {Neurobiological and Clinical Effects of Vitamin D in Psychiatric Symptoms: A Meta-Analysis and Systematic Review},
journal = {Trends in Sciences},
year = {2026},
volume = {23},
number = {8},
pages = {13036},
doi = {10.48048/tis.2026.13036}
}
EUVIMED